# Turtle Beach Corp: financial statements, quarterly

TBCH · Nasdaq · CIK 1493761 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tbch.md) · [Financials](/companies/tbch/financials.md) · [Filings](/companies/tbch/filings.md) · [Insiders](/companies/tbch/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tbch/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [59.2](/filings/0000950170-24-123493.md) | [99.5](/filings/0000950170-24-030883.md) | [55.8](/filings/0000950170-25-067149.md) | [76.5](/filings/0001193125-25-175548.md) | [94.4](/filings/0001193125-25-270035.md) | [146 d](/filings/0001193125-26-104436.md) | [63.9](/filings/0001193125-26-212345.md) | [56.8](/filings/0001193125-26-338384.md) | [80.5](/filings/0001193125-25-270035.md) | [119 d](/filings/0001193125-26-104436.md) | [42.2](/filings/0001193125-26-212345.md) | [56.4](/filings/0001193125-26-338384.md) |
| Cost of revenue | $m | [41.5](/filings/0000950170-24-123493.md) | [67.7 d](/filings/0001193125-26-104436.md) | [38.1](/filings/0000950170-25-067149.md) | [53.4](/filings/0001193125-25-175548.md) | [60.2](/filings/0001193125-25-270035.md) | [92.1 d](/filings/0001193125-26-104436.md) | [40.5](/filings/0001193125-26-212345.md) | [38.5](/filings/0001193125-26-338384.md) | [50.4](/filings/0001193125-25-270035.md) | [71.2 d](/filings/0001193125-26-104436.md) | [30.9](/filings/0001193125-26-212345.md) | [34.5](/filings/0001193125-26-338384.md) |
| Gross profit | $m | [17.7](/filings/0000950170-24-123493.md) | [31.8](/filings/0000950170-24-030883.md) | [17.8](/filings/0000950170-25-067149.md) | [23.1](/filings/0001193125-25-175548.md) | [34.1](/filings/0001193125-25-270035.md) | [54.0 d](/filings/0001193125-26-104436.md) | [23.4](/filings/0001193125-26-212345.md) | [18.3](/filings/0001193125-26-338384.md) | [30.1](/filings/0001193125-25-270035.md) | [47.6 d](/filings/0001193125-26-104436.md) | [11.3](/filings/0001193125-26-212345.md) | [21.9](/filings/0001193125-26-338384.md) |
| Research and development | $m | [4.4](/filings/0000950170-24-123493.md) | [4.5 d](/filings/0001193125-26-104436.md) | [3.9](/filings/0000950170-25-067149.md) | [4.6](/filings/0001193125-25-175548.md) | [4.3](/filings/0001193125-25-270035.md) | [4.5 d](/filings/0001193125-26-104436.md) | [4.0](/filings/0001193125-26-212345.md) | [4.5](/filings/0001193125-26-338384.md) | [4.2](/filings/0001193125-25-270035.md) | [4.3 d](/filings/0001193125-26-104436.md) | [4.6](/filings/0001193125-26-212345.md) | [4.8](/filings/0001193125-26-338384.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(2.5)](/filings/0000950170-24-123493.md) | [8.4 d](/filings/0001193125-26-104436.md) | [(5.7)](/filings/0000950170-25-067149.md) | [(4.1)](/filings/0001193125-25-175548.md) | [6.4](/filings/0001193125-25-270035.md) | [23.4 d](/filings/0001193125-26-104436.md) | [1.5](/filings/0001193125-26-212345.md) | [(0.3)](/filings/0001193125-26-338384.md) | [5.4](/filings/0001193125-25-270035.md) | [20.9 d](/filings/0001193125-26-104436.md) | [(14.1)](/filings/0001193125-26-212345.md) | [(3.1)](/filings/0001193125-26-338384.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.5](/filings/0000950170-24-123493.md) | [(0.0) d](/filings/0001193125-26-104436.md) | [(6.4)](/filings/0000950170-25-067149.md) | [0.8](/filings/0001193125-25-175548.md) | [0.0](/filings/0001193125-25-270035.md) | [(0.0) d](/filings/0001193125-26-104436.md) | [(0.1)](/filings/0001193125-26-212345.md) | [(0.2)](/filings/0001193125-26-338384.md) | [0.3](/filings/0001193125-25-270035.md) | [1.2 d](/filings/0001193125-26-104436.md) | [(0.1)](/filings/0001193125-26-212345.md) | [0.5](/filings/0001193125-26-338384.md) |
| Net income | $m | [(3.6)](/filings/0000950170-24-123493.md) | [8.6](/filings/0000950170-24-030883.md) | [0.2](/filings/0001193125-25-270035.md) | [(7.5)](/filings/0001193125-25-270035.md) | [3.4](/filings/0001193125-25-270035.md) | [20.1 d](/filings/0001193125-26-104436.md) | [(0.7)](/filings/0001193125-26-338384.md) | [(2.9)](/filings/0001193125-26-338384.md) | [1.7](/filings/0001193125-25-270035.md) | [17.6 d](/filings/0001193125-26-104436.md) | [(15.2)](/filings/0001193125-26-338384.md) | [(7.3)](/filings/0001193125-26-338384.md) |
| Diluted EPS | $ per share | [(0.21)](/filings/0000950170-24-123493.md) | [0.47](/filings/0000950170-24-030883.md) | [0.01](/filings/0000950170-25-067149.md) | [(0.35)](/filings/0001193125-25-175548.md) | [0.16](/filings/0001193125-25-270035.md) | not reported | [(0.03)](/filings/0001193125-26-212345.md) | [(0.14)](/filings/0001193125-26-338384.md) | [0.08](/filings/0001193125-25-270035.md) | not reported | [(0.78)](/filings/0001193125-26-212345.md) | [(0.38)](/filings/0001193125-26-338384.md) |
| Basic EPS | $ per share | [(0.21)](/filings/0000950170-24-123493.md) | [0.49](/filings/0000950170-24-030883.md) | [0.01](/filings/0000950170-25-067149.md) | [(0.35)](/filings/0001193125-25-175548.md) | [0.17](/filings/0001193125-25-270035.md) | not reported | [(0.03)](/filings/0001193125-26-212345.md) | [(0.14)](/filings/0001193125-26-338384.md) | [0.09](/filings/0001193125-25-270035.md) | not reported | [(0.78)](/filings/0001193125-26-212345.md) | [(0.38)](/filings/0001193125-26-338384.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [12.3](/filings/0000950170-23-060382.md) | [18.7](/filings/0000950170-25-040292.md) | [17.8](/filings/0000950170-24-054767.md) | [12.5](/filings/0000950170-24-094160.md) | [13.8](/filings/0000950170-24-123493.md) | [13.0](/filings/0001193125-26-104436.md) | [11.7](/filings/0000950170-25-067149.md) | [11.7](/filings/0001193125-25-175548.md) | [12.3](/filings/0001193125-25-270035.md) | [17.0](/filings/0001193125-26-338384.md) | [12.3](/filings/0001193125-26-212345.md) | [19.6](/filings/0001193125-26-338384.md) |
| Current assets | $m | [131](/filings/0000950170-23-060382.md) | [125](/filings/0000950170-25-040292.md) | [141](/filings/0000950170-24-054767.md) | [144](/filings/0000950170-24-094160.md) | [196](/filings/0000950170-24-123493.md) | [188](/filings/0001193125-26-104436.md) | [142](/filings/0000950170-25-067149.md) | [138](/filings/0001193125-25-175548.md) | [178](/filings/0001193125-25-270035.md) | [174](/filings/0001193125-26-338384.md) | [118](/filings/0001193125-26-212345.md) | [125](/filings/0001193125-26-338384.md) |
| Total assets | $m | [156](/filings/0000950170-23-060382.md) | [150](/filings/0000950170-25-040292.md) | [258](/filings/0000950170-24-054767.md) | [264](/filings/0000950170-24-094160.md) | [313](/filings/0000950170-24-123493.md) | [299](/filings/0001193125-26-104436.md) | [247](/filings/0000950170-25-067149.md) | [240](/filings/0001193125-25-175548.md) | [278](/filings/0001193125-25-270035.md) | [269](/filings/0001193125-26-338384.md) | [210](/filings/0001193125-26-212345.md) | [215](/filings/0001193125-26-338384.md) |
| Current liabilities | $m | [74.5](/filings/0000950170-23-060382.md) | [56.3](/filings/0000950170-25-040292.md) | [76.8](/filings/0000950170-24-054767.md) | [103](/filings/0000950170-24-094160.md) | [156](/filings/0000950170-24-123493.md) | [124](/filings/0001193125-26-104436.md) | [72.4](/filings/0000950170-25-067149.md) | [75.3](/filings/0001193125-25-175548.md) | [112](/filings/0001193125-25-270035.md) | [87.7](/filings/0001193125-26-338384.md) | [47.8](/filings/0001193125-26-212345.md) | [52.5](/filings/0001193125-26-338384.md) |
| Total liabilities | $m | [83.9](/filings/0000950170-23-060382.md) | [64.9](/filings/0000950170-25-040292.md) | [133](/filings/0000950170-24-054767.md) | [159](/filings/0000950170-24-094160.md) | [211](/filings/0000950170-24-123493.md) | [178](/filings/0001193125-26-104436.md) | [126](/filings/0000950170-25-067149.md) | [123](/filings/0001193125-25-175548.md) | [168](/filings/0001193125-25-270035.md) | [141](/filings/0001193125-26-338384.md) | [98.1](/filings/0001193125-26-212345.md) | [134](/filings/0001193125-26-338384.md) |
| Long-term debt | $m | not reported | not reported | [46.0](/filings/0000950170-24-054767.md) | [45.8](/filings/0000950170-24-094160.md) | [45.7](/filings/0000950170-24-123493.md) | [45.6](/filings/0001193125-26-104436.md) | [45.5](/filings/0000950170-25-067149.md) | [40.1](/filings/0001193125-25-175548.md) | [48.4](/filings/0001193125-25-270035.md) | [46.3](/filings/0001193125-26-338384.md) | [44.3](/filings/0001193125-26-212345.md) | [76.4](/filings/0001193125-26-338384.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [1.3](/filings/0001193125-26-104436.md) | not reported | not reported | [8.6](/filings/0001193125-25-270035.md) | [8.6](/filings/0001193125-26-338384.md) | [8.6](/filings/0001193125-26-212345.md) | [4.3](/filings/0001193125-26-338384.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | [1.3](/filings/0001193125-25-175548.md) | [1.3](/filings/0000950170-25-067149.md) | [1.7](/filings/0001193125-25-175548.md) | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [72.4](/filings/0000950170-23-060382.md) | [85.1](/filings/0000950170-25-040292.md) | [125](/filings/0000950170-24-054767.md) | [105](/filings/0000950170-24-094160.md) | [102](/filings/0000950170-24-123493.md) | [121](/filings/0001193125-26-104436.md) | [121](/filings/0000950170-25-067149.md) | [117](/filings/0001193125-25-175548.md) | [111](/filings/0001193125-25-270035.md) | [128](/filings/0001193125-26-338384.md) | [112](/filings/0001193125-26-212345.md) | [80.7](/filings/0001193125-26-338384.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(16.3) d](/filings/0000950170-24-123493.md) | [19.1 d](/filings/0001193125-26-104436.md) | [27.3](/filings/0000950170-25-067149.md) | [(12.6) d](/filings/0001193125-25-175548.md) | [(23.2) d](/filings/0001193125-25-270035.md) | [14.3 d](/filings/0001193125-26-104436.md) | [40.5](/filings/0001193125-26-212345.md) | [(3.1) d](/filings/0001193125-26-338384.md) | [(15.2) d](/filings/0001193125-25-270035.md) | [13.3 d](/filings/0001193125-26-104436.md) | [29.4](/filings/0001193125-26-212345.md) | [6.5 d](/filings/0001193125-26-338384.md) |
| Capital expenditure | $m | [0.7 d](/filings/0000950170-24-123493.md) | [0.2 d](/filings/0001193125-26-104436.md) | [0.7](/filings/0000950170-25-067149.md) | [1.2 d](/filings/0001193125-25-175548.md) | [1.4 d](/filings/0001193125-25-270035.md) | [1.5 d](/filings/0001193125-26-104436.md) | [0.2](/filings/0001193125-26-212345.md) | [0.3 d](/filings/0001193125-26-338384.md) | [0.7 d](/filings/0001193125-25-270035.md) | [0.3 d](/filings/0001193125-26-104436.md) | [0.3](/filings/0001193125-26-212345.md) | [0.6 d](/filings/0001193125-26-338384.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-24-123493.md) | [0.0 d](/filings/0001193125-26-104436.md) | not reported | not reported | [10.1 d](/filings/0001193125-25-270035.md) | [2.4 d](/filings/0001193125-26-104436.md) | [1.8](/filings/0001193125-26-212345.md) | [5.0 d](/filings/0001193125-26-338384.md) | [10.3 d](/filings/0001193125-25-270035.md) | [2.0 d](/filings/0001193125-26-104436.md) | [2.2](/filings/0001193125-26-212345.md) | [25.0 d](/filings/0001193125-26-338384.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [16.5](/filings/0000950170-23-060382.md) | [16.6](/filings/0000950170-24-054767.md) | [17.2](/filings/0000950170-24-094160.md) | [17.3](/filings/0000950170-24-123493.md) | [19.4](/filings/0000950170-25-067149.md) | [21.3](/filings/0001193125-25-175548.md) | [21.5](/filings/0001193125-25-270035.md) | [20.5](/filings/0001193125-26-212345.md) | [20.7](/filings/0001193125-26-338384.md) | [20.4](/filings/0001193125-25-270035.md) | [19.5](/filings/0001193125-26-212345.md) | [19.2](/filings/0001193125-26-338384.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 17,909,711 at 2026-07-30, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338384.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.